natgillin/translations-raw huggingface dataset:
– der henviser til sin beslutning af 13. februar 2003 om Kommissionens meddelelse om fællesskabsforanstaltninger og nationale foranstaltninger i relation til brystimplantater P5_TAPROV(2003)0063. ,
– having regard to its resolution of 13 February 2003 on the Commission communication on Community and national measures in relation to breast implants P5-TAPROV(2003)0063. ,
– der henviser til sin beslutning af 15. januar 2003 om Kommissionens meddelelse om den fremtidige ældreomsorg og sundhedspleje P5_TAPROV(2003)0015. ,
– having regard to its resolution of 15 January 2003 on the Commission communication on the future of health care and care for the elderly P5-TAPROV(2003)0015. ,
– der henviser til Europa-Parlamentets og Rådets direktiv 20/2001/EF om indbyrdes tilnærmelse af medlemsstaternes love og administrative bestemmelser om anvendelse af god klinisk praksis ved gennemførelse af kliniske forsøg med lægemidler til human brug EFT L 121 af 1.5.2001, s. 34. ,
– having regard to Directive 2001/20/EC of the European Parliament and of the Council on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use OJ L 121, 1.5.2001, p.
– der henviser til "European Guidelines for Quality Assurance in Mammography Screening" Den tredje udgave, udarbejdet af "European Breast Cancer Network", blev offentliggjort af Kommissionen i 2001. ,
– having regard to the ‘European Guidelines for Quality Assurance in Mammography Screening’ In 2001, the European Commission published the third edition of this European Breast Cancer Network publication. ,
– der henviser til henstillingerne "The requirements of a specialist breast unit" Offentliggjort i "European Journal of Cancer" 36 (2000) 2288-2293. fra "European Society of Mastology" (EUSOMA),
– having regard to the recommendations of the European Society of Mastology (EUSOMA) set out in ‘The requirements of a specialist breast unit’ Published in the European Journal of Cancer 36 (2000) 2288-2293. ,
– der henviser til henstillingerne fra det rådgivende udvalg for kræftforebyggelse om screening for kræft i Den Europæiske Union Offentliggjort i "European Journal of Cancer", 36 (2000) 1473-1478. ,
– having regard to the ‘Recommendations on cancer screening in the European Union’ of the Advisory Committee on Cancer Prevention Published in the European Journal of Cancer, 36 (2000) 1473-1478. ,
– der henviser til betænkning fra Udvalget om Kvinders Rettigheder og Lige Muligheder ( A5‑0159/2003 ),
– having regard to the report of the Committee on Women's Rights and Equal Opportunities ( A5-0159/2003 ),
A. der henviser til, at der ifølge EF-traktatens artikel 152 skal sikres et højt sundhedsbeskyttelsesniveau ved fastlæggelsen og gennemførelsen af alle Fællesskabets politikker og aktiviteter, og at Fællesskabets indsats, der skal være et supplement til de nationale politikker, skal omfatte bekæmpelse af de største trusler mod sundheden, herunder kræft, ved at fremme forskning i deres årsager og forebyggelse samt sundhedsoplysning og -uddannelse,
A. whereas Article 152 of the EC Treaty lays down that a high level of human health protection shall be ensured in the definition and implementation of all Community policies and activities and that Community action, which shall complement national policies, shall be directed towards preventing major health scourges, such as cancer, by promoting research into their causes and their prevention, as well as health information and education,
B. der henviser til, at mere end 216.000 kvinder i EU ifølge WHO i 2000 fik konstateret brystkræft, og at 79.000 kvinder døde heraf; der henviser til, at brystkræft er den hyppigste kræftsygdom hos kvinder, at hver niende kvinde får konstateret denne sygdom, og at brystkræft er den hyppigste dødsårsag hos kvinder i alderen 35-55 år i EU,
B. whereas, in 2000, the World Health Organisation reported more than 216 000 newly diagnosed cases of breast cancer and 79 000 deaths from breast cancer in women, whereas breast cancer is the most frequent cancer affecting women, with one woman in nine suffering from the disease, and whereas breast cancer is the most frequent cause of death in women between the ages of 35 and 55 in the European Union,
C. der henviser til, at ifølge Den Europæiske Unions charter om grundlæggende rettigheder har alle ret til at få adgang til sundhedsforebyggelse og til at modtage lægehjælp,
C. whereas the Charter of Fundamental Rights of the European Union recognises that everyone has the right of access to preventive health care and the right to benefit from medical treatment,
D. der henviser til, at enhver kvinde bør have mulighed for at få foretaget tidlig diagnosticering af høj kvalitet, behandling og efterfølgende kontrol uanset bopæl, social stilling, erhverv og uddannelse, men at der for øjeblikket er markant store forskelle på kvaliteten af brystkræftbehandlingen og dermed også på de pågældende kvinders overlevelseschancer mellem de enkelte medlemsstater, regioner og endda også mellem sygehusene inden for én og samme by,
D. whereas every woman, irrespective of place of residence, social status, occupation and education, should have access to high-quality screening for, treatment of and aftercare in the event of cancer, but whereas huge disparities exist in the quality of breast cancer services and, hence, in the chances of survival of women in the various Member States, the regions and even between individual hospitals in a given city,
E. der henviser til, at der i Eurocare-undersøgelsen fra 1999 blev konstateret en uacceptabel stor forskel på op til16 % med hensyn til brystkræftpatienters overlevelseschancer i de enkelte medlemsstater, som bl.a. skyldtes forskelle i forbindelse med adgang til tidlig diagnosticering, diagnose og behandling Survival of adult cancer patients in Europe diagnosed from 1978-1989: The Eurocare II study,European Journal of Cancer, bd. 34, nr. 14. ,
E. whereas the 1999 Eurocare Study demonstrated in the various Member States unacceptable disparities by up to 16% in the survival rates of breast cancer patients which were attributed, inter alia, to disparities in access to screening, diagnosis and treatment Survival of adult cancer patients in Europe diagnosed from 1978-1989: The Eurocare II study, European Journal of Cancer, Vol.
G. der henviser til, at fællesskabsprogrammet "Europa mod kræft" har givet vigtige impulser til bekæmpelse af brystkræft, idet retningslinjerne fra 1992, "European Guidelines for Quality Assurance in Mammography Screening", er et særligt godt eksempel på kvalitetsstandarder og bedste praksis inden for den europæiske sundhedspolitik,
G. whereas the Community programme entitled ‘Europe Against Cancer’ has given a significant boost to the fight against breast cancer, with the ‘European Guidelines for Quality Assurance in Mammography Screening’, which were originally drawn up in 1992, setting a good example for quality standards and best practice in European health policy,
H. der henviser til, at ifølge WHO kan mammografi-screeninger af høj kvalitet, hvor man regelmæssigt giver den kvindelige befolkning tilbud om at få foretaget gratis mammografi og efterfølgende diagnose som led i et organiseret regionalt og nationalt folkeprogram, føre til en nedgang i brystkræftdødeligheden hos kvinder mellem 50-69 år på op til 35 % og ifølge videnskabelige undersøgelser også hos kvinder i alderen 40-49 år på op til 20 %,
H. whereas, according to the World Health Organisation, high-quality mammography screening, i.e. regular invitations to women to undergo free, voluntary mammographies and follow-up diagnoses as part of an organised population-based regional or national programme, can reduce breast-cancer mortality in women aged between 50 and 69 by up to 35% and whereas, according to scientific studies, breast-cancer mortality in women aged between 40 and 49 can also be reduced by up to 20%,
I. der henviser til, at kvinder med brystproteser skal tilbydes en ultralydsscanning, da det er vanskeligere at foretage en screening af disse kvinder,
I. whereas women with breast implants must be offered ultrasound screening, since they are more difficult to screen,
J. der henviser til, at kvinders selvundersøgelse er et værdifuldt bidrag til observering af kroppen, men at dette ikke kan være et alternativ til tidlig diagnosticering ved hjælp af screening, samt til, at WHO også har konkluderet, at der fortsat ikke foreligger tilstrækkelig dokumentation for, at klinisk undersøgelse eller selvundersøgelse nedbringer brystkræftdødeligheden,
J. whereas breast self‑examination is a valuable tool for increasing women’s self‑awareness of health, although it may never constitute an alternative to early diagnosis based on screening, and whereas the WHO has also concluded that there is still insufficient evidence that clinical breast examination or self‑examination reduces mortality from breast cancer,
K. der henviser til, at undersøgelser ved palpering er en vigtig foranstaltning til rettidig konstatering af karcinomer i tidsrummet mellem to screeningundersøgelser og for kvinder, der som følge af deres alder ikke er berettiget til at deltage i organiserede screeningprogrammer,
K. whereas clinical examination of the breast constitutes an important tool for the early detection of carcinomas in the interval between two screenings and in the case of women who, because of their age, are not entitled to take part in organised screening programmes,
L. der henviser til, at tidlig konstatering, diagnose, behandling og efterbehandling af brystkræft kun bør foretages af et tværfagligt og fuldt uddannet lægeteam, da kvindernes overlevelseschancer derved kan forøges betydeligt,
L. whereas early detection, diagnosis, treatment and aftercare of breast cancer should be performed only by an multidisciplinary team of fully trained physicians, since that may significantly increase the survival rates of the women involved,
M. der henviser til, at en god forebyggelse af brystkræft på mellemlang og lang sigt fører til udgiftsbesparelser inden for sundhedsvæsenet, da man derved kan undgå unødvendige undersøgelser og behandlinger, og så mammakarcinomer derved kan konstateres på et tidligere tidspunkt, og operationer og efterbehandlinger dermed bliver billigere,
M. whereas high-quality breast cancer services may lead to savings for health care systems in the medium and long term, with unnecessary examinations and treatment being avoided and mammary cancer detected at an earlier stage and, therefore, requiring less expensive operations and aftercare,
N. der henviser til, at patienten bør sikres en så høj livskvalitet som muligt, da behandling af brystkræft er en stor belastning, både fysisk og psykisk,
N. whereas the highest possible quality of life must be achieved for patients, since the treatment of breast cancer involves substantial physical and psychological burdens,
O. der henviser til, at kvinder med brystkræft skal orienteres fyldestgørende om diagnose og behandling af den behandlende læge, og at de med hensyn til bivirkninger bør inddrages i beslutninger om terapeutiske muligheder,
O. whereas breast cancer patients should be adequately informed by the attending physician about their diagnosis and treatment and should be involved in decisions about therapy options, while also being made aware of any possible side-effects,
P. der henviser til, at det endnu ikke er alle medlemsstater, som har vedtaget særskilte bestemmelser om patienters rettigheder, og at de relevante rettigheder i øjeblikket derfor er lidet gennemskuelige for patienterne,
P. whereas not all Member States have yet adopted a specific regulation on patients' rights, which means that the relevant rights are currently far from transparent for patients,
2. opfordrer medlemsstaterne til at sætte sig som mål senest i 2008 at skabe forudsætningerne for i EU at reducere brystkræftdødeligheden med 25 % og mindske de nuværende forskelle mellem medlemsstaterne, hvad angår 5-års-overlevelsesraten, til 5 %;
Calls on the Member States to set themselves the target of creating, by 2008, the conditions required for a 25% reduction in the average breast-cancer mortality rate in the EU and of reducing to 5% the disparity between the Member States in the five-year survival rate;
- screeningundersøgelser foretages kun i de dertil beregnede og certificerede centre og i faste eller mobile enheder underlagt disse centre, og i tilfælde af mistanke foretages den efterfølgende diagnose af et tværfagligt lægeteam i et specialcenter, - alle mammografier vurderes uafhængigt af hinanden af to radiologer i dobbelt blindprøve, hvor begge radiologer foretager vurderinger af mammografier af mindst 5.000 kvinder om året, - screeningapparaturets billedkvalitet og strålebelastning kontrolleres regelmæssigt; fremkaldeprocessen bør ligeledes kontrolleres, - læger og medicinsk personale deltager med jævne mellemrum i videreuddannelsesforanstaltninger;
– screening shall take place in dedicated and certified units, or in fixed or mobile units under the authority of such centres, with the assessment of cases with suspicious results also being carried out by a multidisciplinary team in dedicated units, – each mammogram shall be read independently and double-blind by two radiologists, each of whom reads the screening mammograms of a minimum of 5 000 women per year, – the image quality and radiation dose of the screening equipment shall be monitored regularly; the development process should also be checked, – physicians and paramedical staff shall regularly attend further training courses;
5. kræver, at alle kvinder med brystkræft får ret til at blive behandlet af et tværfagligt lægeteam og opfordrer derfor medlemsstaterne til at opbygge et landsdækkende netværk af certificerede tværfaglige brystcentre, der skal opfylde følgende kvalitetsstandarder:
Calls for all women suffering from breast cancer to be entitled to be treated by an multidisciplinary team and calls on the Member States, therefore, to establish a network of certified multidisciplinary breast centres which cover the entire population and fulfil the following criteria:
- på hvert brystcenter opereres der mindst 150 førstediagnosetilfælde af brystkræft om året, - brystcentret ledes af en læge, der er specialiseret og særlig kvalificeret på området for brystsygdomme; det tværfaglige lægeteam består af læger med erfaring i brystkirurgi, som udelukkende foretager brystoperationer, og af radiologer, onkologer, patologer, sygeplejersker og røntgenassistenter, som ligeledes er specialiserede i brystsygdomme, samt af en datamanager, - mindst en gang om ugen gennemføres der tværfaglige patientkonferencer, hvor et tilfælde drøftes såvel præoperativt som postoperativt, - kvaliteten af resultaterne bør sikres gennem klinisk forskning, - læger og medicinsk personale deltager regelmæssigt i videreuddannelsesforanstaltninger, - ved hjælp af en med godt resultat aflagt prøve dokumenterer læger og medicinsk personale regelmæssigt, at de råder over fyldestgørende aktuel viden og sagkundskab, - kontrolundersøgelser og efterbehandlinger gennemføres i tæt samarbejde med det pågældende tværfaglige brystcenter, - patienterne modtager kræftpsykologisk rådgivning, psykoterapeutisk støtte og psykoterapeutiske behandlinger og har adgang til sociale ydelser;
– each breast centre shall perform a minimum of 150 primary breast cancer operations per year, – each breast centre shall operate under the direction of a highly qualified physician who specialises in breast disease, while the multidisciplinary team shall consist of physicians experienced in and performing only breast surgery, together with radiologists, oncologists, pathologists, nurses and radiographers who also specialise in breast disease, as well as a data manager, – multidisciplinary pre-operative and post-operative case conferences shall be held at least once a week, – the quality of the results shall be guaranteed by means of clinical research, – physicians and paramedical staff shall regularly attend further training courses, – physicians and paramedical staff shall be required to pass a test at regular intervals to show that they have sufficient up-to-date knowledge and skills, – follow-up and aftercare examinations shall be carried out in close cooperation with the relevant multidisciplinary breast centre, – patients shall receive onco-psychological counselling, psychotherapeutic support and physiotherapy services, as well as social services;
a) at sikre en bedre koordinering mellem national og europæisk forskning, b) at sikre, at dokumentationsbaseret medicin også danner grundlag for brystkræftbehandling i Europa, c) hurtigst muligt at inddrage fremskridt i grundforskningen i behandlingen samt fremme den kliniske forskning yderligere, navnlig de kliniske tests, der samordnes af den europæiske organisation for kræftforskning og -behandling (EORTC) og gennemføres i kræftcentre og -klinikker i hele EU, d) at afsætte flere midler end hidtil til brystkræftforskning for - yderligere at intensivere forskningen i årsager og terapeutiske metoder, - at forbedre prognosen for behandlingens virkning og resultatets sikkerhed, - at øge forskningen i sammenhængen mellem brystkræft og potentielle risikofaktorer som f.eks. tobak, ernæring, hormoner og livsstil (kropsvægt, fysiske aktiviteter), - nærmere at forske i stationære eller ambulante behandlingsforløb, således at patienterne fremover ikke lider mere end højst nødvendigt som følge af hospitalsophold og medicinindtagelse. - at udvikle en metode til standardiseret risikovurdering af kvinder, der har eventuelt arvelige anlæg for at få brystkræft;
(a) ensure more effective coordination between national and European research, (b) ensure that evidence‑based medicine also constitutes the basis for breast cancer treatment in Europe, (c) incorporate the positive findings of fundamental research into treatment as soon as possible and further strengthen clinical research, in particular the clinical trials coordinated by the European Organisation for Research and Treatment of Cancer (EORTC) and conducted in cancer centres and clinics across the European Union, (d) provide more funding than in the past for breast cancer research in order to: – step up the search for the causes of the disease and for forms of therapy, – improve prediction of the effect of treatment and certainty of outcomes, – further investigate the relationship between breast cancer and potential risk factors such as tobacco, diet, hormones and life-style (body weight, physical activity), – increase research into in-patient and out-patient treatment protocols, with a view to reducing the unnecessary burden on patients of clinical and medical treatment services, – develop a method for the standardised risk assessment of women potentially in danger of developing a hereditary breast disease;
a) inden for rammerne af handlingsprogrammet på området for folkesundhed (2003-2008) også fremover i tilstrækkeligt omfang at fremme de innovative projekter, der blev udarbejdet under det hidtidige program "Europa mod kræft", som f.eks.
Calls on the European Commission to:
9. understreger betydningen af kliniske undersøgelser for medicinske fremskridt; glæder sig over vedtagelsen af EU-direktivet om indbyrdes tilnærmelse af medlemsstaternes love og administrative bestemmelser om anvendelse af god klinisk praksis ved gennemførelse af kliniske forsøg med lægemidler til human brug (2001/20/EF); er af den opfattelse af gennemførelsesbestemmelserne må affattes under hensyntagen til forskningsorganisationernes behov; er foruroliget over, at målet om harmonisering af love og administrative bestemmelser om klinisk forskning ikke er nået, og at de bestående hindringer for kliniske forsøg med deltagelse af flere medlemsstater ikke er blevet fjernet;
Emphasises the importance of clinical studies for medical progress; welcomes the adoption of Directive 2001/20/EC on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use; believes that the requirements of research bodies should be taken into account when the relevant implementing provisions are being drafted, that the objective of the harmonisation of the legal and regulatory arrangements for clinical research will not be attained and that the current obstacles to clinical studies involving several Member States will not be eliminated;
12. opfordrer Kommissionen til sammen med det italienske rådsformandskab i slutningen af 2003, når de sidste projekter udløber, at afholde en konference for bl.a. med henblik på det nye handlingsprogram for sundhed (2003-2008) at gøre endelig status over programmet "Europa mod kræft";
Calls on the Commission to organise a conference, jointly with the Italian Presidency in late 2003, when the final projects are coming to an end, in order to draw up a final summary of the successes and failures of the ‘Europe Against Cancer’ programme, partly with a view to the new action programme in the field of public health (2003-2008);
Siden anden Verdenskrig er antallet af nye tilfælde af brystkræft (forekomsten af brystkræft) hos kvinder steget på verdensplan.
Since the end of the Second World War, the number of new cases of breast cancer in women (breast-cancer incidence) has been increasing world wide.
Brystkræft er i dag den hyppigste kræftsygdom hos kvinder i EU.
Today, breast cancer is the most common disease affecting women in the European Union.
Brystkræft er den hyppigste dødsårsag hos kvinder i alderen 35-55 år.
Breast cancer is the most common cause of death in women between the ages of 35 and 55.
På verdensplan kan der i alle industrilande med undtagelse af Japan konstateres en høj forekomst af brystkræft, men der er dog store forskelle landene imellem.
World wide, every industrialised nation, except Japan, has a high incidence rate, but there are large disparities in such rates among the individual countries.
Den højeste forekomst af brystkræft i Europa findes i regionerne i Vest- og Nordeuropa, mens tallene er lavere i Syd- og Østeuropa.
In Europe, the regions in western and northern Europe have the highest incidence rates, while countries in southern and eastern Europe have lower incidence rates.
I Vesteuropa er risikoen for at få brystkræft 60 % højere end i Østeuropa.
The risk of developing breast cancer is 60% higher in western Europe than in eastern Europe.
I 2000 var landene med den højeste procentsats for brystkræft GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Wordwide, Version 1.0.
In 2000, the Member States with the highest incidence rates GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, Version 1.0.
Internet: http://www-dep.iarc.fr/globocan/globocan.html (nye tilfælde pr. 100.000 kvinder) Nederlandene (91,6), Danmark (86,2), Frankrig (83,2), Belgien (82,2) og Sverige (81), mens øvrige lande som f.eks. Grækenland (47,6) og Spanien (47,9) samt tiltrædelseslande som Litauen (39,8) og Letland (42,2) kunne fremvise betydeligt lavere procentsatser.
Internet: http://www-dep.iarc.fr/globocan/globocan.html. (morbidity per 100 000 women) were the Netherlands (91.6), Denmark (86.2), France (83.2), Belgium (82.2) and Sweden (81), while other Member States such as Greece (47.6) and Spain (47.9) and applicant countries such as Lithuania (39.8) and Latvia (42.2) had much lower rates.
I de fleste medlems- og tiltrædelseslande stiger antallet for nye tilfælde af brystkræft årligt med ca. 1,5 %.
In most of the Member States and applicant countries, the number of new cases of breast cancer is increasing annually by about 1.5 %.